Author Archives: Modulight Content

About Modulight Content

Modulight wants to share high-quality scientific publications, white papers, application notes, and other articles. The articles shared are courtesy of the authoring researchers and groups and we're thankful for giving us the permission to honor their work this way. If you have something to share please drop us a line (see the contact form at Contact Us section).

Modulight Spotlights: LASER-SHARP RESEARCH – April 2024

April 10, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – April 2024 First-in-human, phase 1 clinical trial results with ML7710 have been published in a renowned journal Radiology by Timothy Baran and team at University of Rochester Medical Center. The trial investigated treatment of deep tissue abscesses using photodynamic therapy with methylene blue and ML7710 laser. Abscesses are painful collection of pus, usually caused by a bacterial infection. Standard treatment is abscess drainage and antibiotics, however treatment responses vary widely and are linked to prolonged hospital stay, costs, and patient discomfort, as well as increasing concerns for antibiotic-resistance. The trial in 18 Continue reading →

AI-based laser alignment for Flow Cytometry

April 4, 2024 by Modulight Content
No comments
Next generation flow cytometry Lasers have been historically the key light sources utilized in flow cytometry due to their ability to deliver the precise amount of energy needed to trigger the Stokes shift, which is the key phenomena underlying flow cytometry operation. For the same reason lasers and optical system in general are referred to as the “heart of flow cytometer”, since they are the integral component initiating the instrument operation. To ensure smooth and repeatable flow cytometer performance laser source needs to exhibit excellent Continue reading →

Photobiomodulation for pain treatment using ML6600

March 15, 2024 by Modulight Content
No comments
Background Photobiomodulation with low-level laser or light therapy is an effective treatment for pain. It has various effects, such as analgesic (pain-relieving) effects, anti-inflammatory effects, tissue regeneration promoting effects, and wound healing effects. Photobiomodulation can be used to relief both acute and chronic pain and has the advantage of being noninvasive and safe. Earlier studies have shown that photobiomodulation affects the activity of pain-transmitting nerves, even though the mechanisms are not fully understood. Because lasers are scattered and absorbed by biological tissues, the laser intensity Continue reading →Customer case University of Toyama is a Japanese national university located in Toyama City and Takaoka City and established in 1949. It is comprised of 3 former national universities Toyama University, Toyama Medical and Pharmaceutical University, and Takaoka National College. Naoya Ishibashi Daisuke Uta Modulight products: ML6600 Laser use: Studying pain treatment with photobiomodulation. Links to articles:     Background Photobiomodulation with low-level laser or light therapy is an effective treatment for pain. It has various effects, such as analgesic (pain-relieving) effects, anti-inflammatory effects, tissue regeneration Continue reading →

Phototruncation cell tracking with near-infrared photoimmunotherapy using heptamethine cyanine dye to visualise migratory dynamics of immune cells

March 14, 2024 by Modulight Content
No comments
Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi  Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi A new method called phototruncation-assisted cell tracking (PACT) can be used to noninvasively track migration of immune cells to understand anti-cancer immunity mechanisms. PACT is based on irreversible photo-induced truncation reaction, transforming Cy7 into Cy5 when exposed to NIR light (780 nm). PACT was used in this study to monitor spatiotemporal migration of immune cells between tumor and Continue reading →

Development of thermosensitive liposomes with the help of ML8500

March 13, 2024 by Modulight Content
No comments
Background The proper delivery and release of therapeutic drugs to a specific site or cell type is one of the main challenges in the treatment of diseases. Liposomes, which are vesicles composed of lipids, serve as carriers for drug delivery thanks to their long circulation time. This results to reduced toxicity in healthy tissues and improved therapeutic efficacy of encapsulated drugs. However, conventional liposomes can often be even too stabile, leading to insufficient drug release at the target site. Light activation can offer a solution Continue reading →Customer case Pharmaceutical Nanotechnology led by Professor Timo Laaksonen on controlled drug release and delivery using modern methods and materials. Particular interest lies in using light to both monitor nanomaterial behavior and to trigger e.g. drug release processes. Modulight products: ML8500, ML6600, MLAKIT Prof. Timo Laaksonen Dr. Tatu Lajunen Laser use: Light-triggered drug release studies from light-activated liposomes. ML8500 with 808 nm wavelength was used to induce the release of calcein from liposomes under different temperatures. The effect of different type of lipids on liposomal Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – March 2024

March 7, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – March 2024 Glioblastoma is the most aggressive type of brain tumor. It is hard to treat because of its invasion into functioning brain tissues, limited drug delivery due to blood-brain-barrier, and evolved treatment resistance. To address these challenges, a light-activated nanoformulation, called nanoVP, was developed for glioblastoma in a new study co-led by John Quinlan and Collin Inglut in Dr. Huang’s team at the University of Maryland. Published in a prestigious journal Advanced Science, this novel therapy resulted in an improved tumor control and survival Continue reading →

Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery

March 6, 2024 by Modulight Content
No comments
Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland  Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland Glioblastoma (GBM) is hard to treat due to cellular invasion into functioning brain tissues, limited drug delivery, and evolved treatment resistance. Recurrence is nearly universal even after surgery, chemotherapy, and radiation. Photodynamic therapy (PDT) involves photosensitizer administration followed by light activation to generate reactive oxygen species at tumor sites, thereby killing cells or Continue reading →

ML7710 for photoactivated treatment of lung cancer

March 6, 2024 by Modulight Content
No comments
Deadliest cancer Precision with photoactivation Photoimmunotherapy with ML7710 offers a clinical therapeutic option for NSCLC patients even with advanced disease stage. Besides laser light, this therapy involves photoactivated drug, which can be activated precisely at the tumor site with laser fibers, hence minimizing drug effects to healthy tissues. Smaller invasiveness compared to surgery can enable patients to stay less time recovering at the hospital. It can also be repeated if needed multiple times without cumulating toxicities, unlike radiation therapy. Some previously inoperable tumors can decrease Continue reading →Deadliest cancer Lung cancer is the leading cause of cancer deaths worldwide, with more than 2.2 million cases and 1.8 million deaths each year [1]. Lung cancer can be divided into two types, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with the latter accounting for about 85% of all lung cancer cases. NSCL is usually less sensitive to chemo- and radiotherapy and in many cases tumor cannot be removed surgically or has spread from lungs to distant sites at the time Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – February 2024

February 29, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – February 2024 Photoactivated chemotherapy (PACT) is a novel anticancer therapy where cytotoxic drug is attached into a photocage, which is cleaved by light to release the drug at the tumor site. A new study led by Prof. Sylvestre Bonnet’s group at Leiden University, demonstrated a significantly improved agent for photoactivated chemotherapy. ML6600 laser was used to study the drug release from the photocage, comparing efficacy between red and green light. It was shown that the agent could be effectively released Continue reading →

Modulight Announces Involvement in GlioLighT Project for Glioma Treatment

February 14, 2024 by Modulight Content
No comments
Modulight is pleased to announce its participation in the GlioLighT project, aimed at developing new treatment options for gliomas. This project has received substantial funding of approximately EUR 2.2 million over three years from the European Innovation Council’s Pathfinder program. The GlioLighT project partners include Johannes Gutenberg University Mainz, Aston University in Birmingham, the University of Barcelona, LMU Munich, and MODUS Research and Innovation Ltd. The budgetary allotment of the project for Modulight is about EUR 400,000 over the duration of the project. Gliomas, known Continue reading →Modulight is pleased to announce its participation in the GlioLighT project, aimed at developing new treatment options for gliomas. This project has received substantial funding of approximately EUR 2.2 million over three years from the European Innovation Council's Pathfinder program. The GlioLighT project partners include Johannes Gutenberg University Mainz, Aston University in Birmingham, the University of Barcelona, LMU Munich, and MODUS Research and Innovation Ltd. The budgetary allotment of the project for Modulight is about EUR 400,000 over the duration of the project. Gliomas, known Continue reading →